Profile | GDS2987 / hmm23531-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 3.8 | 14 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 16.5 | 48 |
GSM215254 | HMVEC_atorvastatin_rep1 | 8.1 | 22 |
GSM215282 | HMVEC_atorvastatin_rep3 | 12.5 | 29 |
GSM215344 | HMVEC_atorvastatin_rep2 | 11.8 | 29 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 15.6 | 31 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 22.8 | 36 |
GSM215294 | HMVEC_SLx2119_rep1 | 13.1 | 43 |
GSM215295 | HMVEC_SLx2119_rep2 | 14.6 | 29 |
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 6.9 | 11 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 8 | 13 |
GSM215311 | PASMC_atorvastatin_rep1 | 18.4 | 31 |
GSM215312 | PASMC_atorvastatin_rep2 | 30 | 43 |
GSM215313 | PASMC_atorvastatin_rep3 | 16.4 | 24 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 32.8 | 48 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 17.2 | 32 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 11.2 | 19 |
GSM215327 | PASMC_SLx2119_rep1 | 8.8 | 16 |
GSM215328 | PASMC_SLx2119_rep2 | 0.3 | 1 |
GSM215329 | PASMC_SLx2119_rep3 | 17.6 | 33 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 6.7 | 19 |
GSM215332 | Fibroblasts_vehicle_rep3 | 11.4 | 36 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 4.1 | 11 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | 17.1 | 39 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 17.1 | 49 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 14.9 | 43 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 8 | 22 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 17.4 | 45 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 25.9 | 56 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 17.7 | 41 |